Roth Capital raised the firm’s price target on Verona Pharma (VRNA) to $92 from $83 and keeps a Buy rating on the shares after its Q1 results. The company’s Ohtuvayre’s launch performance continues to impress, achieving $71.3M in product sales in Q1 – up 95% from Q4 – and with prescriptions growing by 56%, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRNA:
- Verona Pharma price target raised to $90 from $83 at BTIG
- Verona Pharma price target raised to $106 from $72 at Canaccord
- Verona Pharma’s Strong Market Performance and Strategic Advancements Justify Buy Rating and Increased Price Target
- Verona Pharma price target raised to $85 from $75 at H.C. Wainwright
- Verona Pharma Reports Strong Q1 2025 Earnings